Home/Medigene/Dr. Selwyn Ho
DS

Dr. Selwyn Ho

Chief Financial Officer

Medigene

Therapeutic Areas

Medigene Pipeline

DrugIndicationPhase
MDG1011Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Multiple Myeloma (MM)Phase I/II
MDG1021Solid TumorsPreclinical
TCR Library ProgramVarious Solid TumorsDiscovery